Efficacy and safety of Endostar combined with vinorelbine and cisplatin for the treatment of advanced non-small cell lung cancer: a comparative study

This study aimed to investigate short-and long-term efficacy of continuous administration of Endostar (YH16) combined with vinorelbine (NVB) and cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC). A total of 232 NSCLC patients were assigned into the YH-16 + NP group (n = 116, treatment with YH-16, NVB, and DDP) and NP group (n = 116, treatment with NVB and DDP). The rates of efficiency and clinical benefit, progression-free survival (PFS), adverse effects, and quality of life (QOL) were compared between the two groups. A multivariate Cox regression model was conducted for independent risk factors for prognosis of NSCLC. The rates of efficiency, clinical benefit, PFS, and median PFS were higher in the YH-16 + NP group than those in the NP group. The multivariate Cox regression model demonstrated that pathological classification, tumor-node-metastasis (TNM) staging, number of metastatic lesions, and treatment allocation were independent risk factors for prognosis of NSCLC. No statistical difference was observed in the incidence of adverse reactions. The Karnofsky performance scores were decreased both in the NP and YH-16 + NP groups before and after treatment while no significant difference was observed in KPS between these two groups. These findings indicate that compared with single NP regimen, the YH-16 + NP regimen shows better efficacy and safety in treatment of advanced NSCLC.